Efficacy and safety of iron chelator for transfusion-dependent patients with myelodysplastic syndrome: a meta-analysis

References

• Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383:2239–2252. doi: 10.1016/S0140-6736(13)61901-7
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Koller C, et al. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer. 2008;112:1089–1095. doi: 10.1002/cncr.23280
   PubMed Web of Science ®Google Scholar
• Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–7603. doi: 10.1200/JCO.2005.01.7038
   PubMed Web of Science ®Google Scholar
• Cazzola M, Malcovati L. Myelodysplastic syndromes — coping with ineffective hematopoiesis. N Engl J Med. 2005;352:536–538. doi: 10.1056/NEJMp048266
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015;29:1502–1513. doi: 10.1038/leu.2015.55
   PubMed Web of Science ®Google Scholar
• Killick SB, Carter C, Culligan D, et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol. 2014;164:503–525. doi: 10.1111/bjh.12694
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–3510. doi: 10.1200/JCO.2006.08.5696
   PubMed Web of Science ®Google Scholar
• Temraz S, Santini V, Musallam K, et al. Iron overload and chelation therapy in myelodysplastic syndromes. Crit Rev Oncol Hematol. 2014;91:64–73. doi: 10.1016/j.critrevonc.2014.01.006
   PubMed Web of Science ®Google Scholar
• Porter JB. A risk-benefit assessment of iron-chelation therapy. Drug Saf. 1997;17:407–421. doi: 10.2165/00002018-199717060-00006
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Rigsby CK, Stone RM, et al. NCCN task force: transfusion and iron overload in patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2009;7(Suppl. 9):S1–S16. doi: 10.6004/jnccn.2009.0082
   PubMedGoogle Scholar
• Bennett JM, MDS Foundation's Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83:858–861. doi: 10.1002/ajh.21269
   PubMed Web of Science ®Google Scholar
• Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78:487–494. doi: 10.1111/j.1600-0609.2007.00842.x
   PubMed Web of Science ®Google Scholar
• Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res. 2007;31:S7–S9. doi: 10.1016/S0145-2126(07)70460-5
   PubMed Web of Science ®Google Scholar
• De Domenico I, Ward DM, Kaplan J. Specific iron chelators determine the route of ferritin degradation. Blood. 2009;114:4546–4551. doi: 10.1182/blood-2009-05-224188
   PubMed Web of Science ®Google Scholar
• Cermak J, Kacirkova P, Mikulenkova D, et al. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res. 2009;33:1469–1474. doi: 10.1016/j.leukres.2009.06.033
   PubMed Web of Science ®Google Scholar
• Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res. 2007;31(Suppl 3):S2–S6. doi: 10.1016/S0145-2126(07)70459-9
   PubMed Web of Science ®Google Scholar
• Neukirchen J. Iron chelation in MDS: still a controversial issue. Leuk Res. 2014;38:145–146. doi: 10.1016/j.leukres.2013.12.004
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269. doi: 10.7326/0003-4819-151-4-200908180-00135
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605. doi: 10.1007/s10654-010-9491-z
   PubMed Web of Science ®Google Scholar
• Hao Y, Fu AZ, Coe A, et al. Clinical outcomes among patients with myelodysplastic syndromes treated with iron chelation therapy: a real world medicare database study. Blood. 2016;128:2396–2396.
   Web of Science ®Google Scholar
• Zeidan AM, Hendrick F, Friedmann E, et al. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. J Comp Eff Res. 2015;4:327–340. doi: 10.2217/cer.15.20
   PubMed Web of Science ®Google Scholar
• Lyons RM, Marek BJ, Paley C, et al. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years. Leuk Res. 2017;56:88–95. doi: 10.1016/j.leukres.2017.01.033
   PubMed Web of Science ®Google Scholar
• Remacha AF, Arrizabalaga B, Villegas A, et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol. 2015;94:779–787. doi: 10.1007/s00277-014-2274-y
   PubMed Web of Science ®Google Scholar
• Raptis A, Duh MS, Wang ST, et al. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion. 2010;50:190–199. doi: 10.1111/j.1537-2995.2009.02361.x
   PubMed Web of Science ®Google Scholar
• Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res. 2010;34:864–870. doi: 10.1016/j.leukres.2009.12.004
   PubMed Web of Science ®Google Scholar
• Neukirchen J, Fox F, Kundgen A, et al. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res. 2012;36:1067–1070. doi: 10.1016/j.leukres.2012.04.006
   PubMed Web of Science ®Google Scholar
• Parmar A, Leitch HA, Wells RA, et al. Iron chelation is associated with improved survival adjusting for disease and patient related characteristics in Low/Int-1 risk MDS at the time of first transfusion dependence: a MDS-CAN study. Blood. 2015;126:1701–1701.
   Web of Science ®Google Scholar
• Komrokji RS, Ali NHA, Padron E, et al. Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS patients treated at the Moffitt Cancer Center. Blood. 2011;118:2776–2776.
   Google Scholar
• Wong SA, Leitch HA. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit? Leuk Res. 2018;64:24–29. doi: 10.1016/j.leukres.2017.11.005
   PubMed Web of Science ®Google Scholar
• Delforge M, Selleslag D, Beguin Y, et al. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res. 2014;38:557–563. doi: 10.1016/j.leukres.2014.02.003
   PubMed Web of Science ®Google Scholar
• Wong CAC, Wong SAY, Leitch HA. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy. Leuk Res. 2018;67:75–81. doi: 10.1016/j.leukres.2018.02.005
   PubMed Web of Science ®Google Scholar
• Leitch HA, Parmar A, Wells RA, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017;179:83–97. doi: 10.1111/bjh.14825
   PubMed Web of Science ®Google Scholar
• Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366:348–359. doi: 10.1056/NEJMra1004967
   PubMed Web of Science ®Google Scholar
• Gattermann N. Iron overload in myelodysplastic syndromes (MDS). Int J Hematol. 2018;107:55–63. doi: 10.1007/s12185-017-2367-1
   PubMed Web of Science ®Google Scholar
• Abraham I, Yami MA, Yun S, et al. Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: review and pooled analysis of observational studies. Leuk Res. 2017;57:104–108. doi: 10.1016/j.leukres.2017.03.007
   PubMed Web of Science ®Google Scholar
• Porter JB. Practical management of iron overload. Br J Haematol. 2001;115:239–252. doi: 10.1046/j.1365-2141.2001.03195.x
   PubMed Web of Science ®Google Scholar
• Payne KA, Rofail D, Baladi JF, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther. 2008;25:725–742. doi: 10.1007/s12325-008-0085-z
   PubMed Web of Science ®Google Scholar
• Bou-Fakhredin R, Bazarbachi AH, Chaya B, et al. Iron overload and chelation therapy in non-transfusion dependent thalassemia. Int J Mol Sci. 2017;18:2778–2786. doi: 10.3390/ijms18122778
   Web of Science ®Google Scholar
• Borgna-Pignatti C, Marsella M. Iron chelation in thalassemia major. Clin Ther. 2015;37:2866–2877. doi: 10.1016/j.clinthera.2015.10.001
   PubMed Web of Science ®Google Scholar
• Meerpohl JJ, Antes G, Rücker G, et al. Deferasirox for managing iron overload in people with myelodysplastic syndrome. Cochrane Database Syst Rev. 2010;10:1–39.
   Google Scholar
• Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw. 2006;4:91–96. doi: 10.6004/jnccn.2006.0010
   PubMedGoogle Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: 10.1186/1745-6215-8-16
   PubMed Web of Science ®Google Scholar
• Spruance SL, Reid JE, Grace M, et al. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48:2787–2792. doi: 10.1128/AAC.48.8.2787-2792.2004
   PubMed Web of Science ®Google Scholar
• Messa E, Carturan S, Maffe C, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010;95:1308–1316. doi: 10.3324/haematol.2009.016824
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52. doi: 10.1182/blood-2008-01-134858
   PubMed Web of Science ®Google Scholar